A Study to Evaluate the Efficacy and Safety of AD-209

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 221 participants.

Also called NCT05631990

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 221 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05631990
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05631990. Randomized; double masking; primary purpose treatment. Start 2023-04-05 (actual); primary completion 2023-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of AD-209
Condition
Hypertension, Essential
Intervention (Drug)
AD-209
Intervention (Drug)
AD-209-1A
Intervention (Drug)
AD-209-1B
Intervention (Drug)
AD-209-1C
Intervention (Drug)
AD-209 placebo
Intervention (Drug)
AD-209-1 placebo
Lead sponsor
Addpharma Inc. (class: industry)

Record details

Record id
cardio:ct-nct05631990
Content hash
b22168553b6be5622c23f41d6fbf14c0af5c174c12d3da143a984d878d782ee5